ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 06/14/2011

ClinicalTrials.gov ID: NCT00296400

Study Identification

Unique Protocol ID:	D3569C00011
Brief Title:	Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (PLANET II)
Official Title:	Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria
Secondary IDs:	PLANET II

Study Status

Record Verification:	June 2011
Overall Status:	Completed
Study Start:	February 2006
Primary Completion:	June 2009 [Actual]
Study Completion:	June 2009 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	
Collaborators:	

Oversight

FDA Regulated?:	Yes

Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No
IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: 56,385 Serial Number: 539 Has Expanded Access? No
Review Board:	Approval Status: Board Name: Board Affiliation: Phone: Email:
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	United States: Food and Drug Administration Bulgaria: Drug Agency Romania: Ministry of Health and the Family Italy: National Institute of Health Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy Canada: Health Protection Branch Denmark: Federal Institute for Drugs and Medicinal Devices Brazil: Agencia Nacional de Viglancia Sanitaria Mexico: Comision Federal para la Proteccion Contra Riesgos Sanitarios South Africa: Medicines Control Council

Study Description

Brief Summary:	The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
Detailed Description:	

Conditions

Conditions:	Hyperlipidemia
Keywords:	Hyperlipidemia Proteinuria Diabetes Mellitus

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	
Masking:	Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	237 [Actual]

Arms and Interventions

Intervention Details:

Drug: Rosuvastatin

Other Names:

- Crestor

Drug: Atorvastatin

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	
Gender:	Both
Accepts Healthy Volunteers?:	No
Criteria:	Inclusion Criteria:

- greater than or equal to 18 years of age
- Hyperlipidemia
- Urinary protein

Exclusion Criteria:

- Previous rosuvastatin treatment < 6 months prior to Visit 1
- Statin intolerance
- Severe hypertension
- Diabetes

Contacts/Locations

Study Officials: AstraZeneca Crestor Medical Science Director, MD
Study Director
AstraZeneca

Locations: Brazil
Research Site
Curitiba, PR, Brazil

Research Site
Sao Paulo, SP, Brazil

Bulgaria
Research Site
Blagoevgrad, Bulgaria

Research Site
Burgas, Bulgaria

Research Site
Gabrovo, Bulgaria

Research Site
Pleven, Bulgaria

Research Site
Plovdiv, Bulgaria

Research Site
Sofia, Bulgaria

Research Site
Varna, Bulgaria

Research Site
Veliko Turnovo, Bulgaria

Canada, Ontario
Research Site
Courtice, Ontario, Canada

Research Site
East York, Ontario, Canada

Canada, Quebec
Research Site
Greenfield Park, Quebec, Canada

Research Site
Montreal, Quebec, Canada

Canada, Ontario
Research Site
Oakville, Ontario, Canada

Research Site
Oshawa, Ontario, Canada

Research Site
Richmond Hill, Ontario, Canada

Research Site
Scarborough, Ontario, Canada

Canada, Newfoundland and Labrador
Research Site
St John's, Newfoundland and Labrador, Canada

Canada, Ontario
Research Site
Thunder Bay, Ontario, Canada

Research Site
Toronto, Ontario, Canada

Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada

Denmark
Research Site
Fredericia, Denmark

Research Site
Herlev, Denmark

Research Site
Holbaek, Denmark

Research Site
Kobenhavn, Denmark

Research Site
Roskilde, Denmark

Research Site
Viborg, Denmark

Germany
Research Site
Berlin, Germany

Research Site
Cloppenburg, Germany

Research Site
Demmin, Germany

Research Site
Dusseldorf, Germany

Research Site
Elsenfeld, Germany

Research Site
Gottingen, Germany

Research Site
Hannover, Germany

Research Site
Wurzburg, Germany

Hungary
Research Site
Ajka, Hungary

Research Site
Baja, Hungary

Research Site
Balatonfured, Hungary

Research Site
Budapest, Hungary

Research Site
Debrecen, Hungary

Research Site
Eger, Hungary

Research Site
GY�R, Hungary

Research Site
Gyula, Hungary

Research Site
Keszthely, Hungary

Research Site
Miskolc, Hungary

Research Site
Nyiregyhaza, Hungary

Research Site
Szolnok, Hungary

Research Site
Szombathely, Hungary

Research Site
Zalaegerszeg, Hungary

Italy
Research Site
Acireale, CT, Italy

Research Site
Bergamo, BG, Italy

Research Site
Bologna, BO, Italy

Research Site
Brescia, BS, Italy

Research Site
Castelfranco Veneto, TV, Italy

Research Site
Firenze, FI, Italy

Research Site
Foggia, FG, Italy

Research Site
Mestre, VE, Italy

Research Site
Parma, PR, Italy

Research Site
Reggio Calabria, RC, Italy

Research Site
Sassari, SS, Italy

Research Site
Teramo, TE, Italy

Research Site
Torino, TO, Italy

Research Site
Treviso, TV, Italy

Mexico
Research Site
Aguascalientes, Mexico

Research Site
Cuernavaca, Morelos, Mexico

Research Site
D.F, Mexico, Mexico

Research Site
Durango, Mexico

Research Site
Mexico, DF, Mexico

Research Site
SAN LUIS POTOS&#65533;, MEXICO, Mexico

Research Site
Zapopan, Jalisco, Mexico

Romania
Research Site
Brasov, Brasov, Romania

Research Site
Bucuresti, Romania

Research Site
Cluj Napoca, Cluj, Romania

Research Site
Constanta, Constanta, Romania

Research Site
Craiova, Romania

Research Site
Iasi, Romania

Research Site
Suceava, Suceava, Romania

Research Site
Timisoara, Timis, Romania

South Africa
Research Site
Cape Town, South Africa

Research Site
Durban, South Africa

Research Site
Parow, W Cape, South Africa

Research Site
Pretoria, South Africa, South Africa

Research Site
Johannesburg, Gauteng, South Africa

United States, Georgia
Research Site
Augusta, Georgia, United States

United States, Arizona
Research Site
Avondale, Arizona, United States

United States, Florida
Research Site
Clearwater, Florida, United States

United States, Maryland
Research Site
Columbia, Maryland, United States

United States, Missouri
Research Site
Columbia, Missouri, United States

United States, South Carolina
Research Site
Columbia, South Carolina, United States

United States, Michigan
Research Site
Detroit, Michigan, United States

United States, Washington
Research Site
Gig Harbor, Washington, United States

United States, Florida
Research Site
Hollywood, Florida, United States

United States, Texas
Research Site
Houston, Texas, United States

United States, Florida
Research Site
Jacksonville, Florida, United States

United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States

United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States

United States, New York
Research Site
Orchard Park, New York, United States

United States, California
Research Site
Pasadena, California, United States

United States, Arizona
Research Site
Phoenix, Arizona, United States

United States, Pennsylvania
Research Site
Pittsburgh, Pennsylvania, United States

United States, Virginia
Research Site
Richmond, Virginia, United States

United States, California
Research Site
Riverside, California, United States

United States, Texas
Research Site
San Antonio, Texas, United States

United States, Massachusetts
Research Site
Springfield, Massachusetts, United States

United States, Kansas
Research Site
Topeka, Kansas, United States

United States, North Carolina
Research Site

Winston Salem, North Carolina, United States

References

Citations:

Links: URL: http://www.astrazeneca.com/node/emailtriage.aspx
Description AstraZeneca Clinical Trial Information - Outside US

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.
Pre-Assignment Details	237 patients [pts] completed the 8-week lead-in period and were randomized. The most common reasons for discontinuation during the lead in period included incorrect enrollment (466 pts), development of study-specific discontinuation criteria (41 pts), and voluntary discontinuation (29 pts). 189 patients completed the study.

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Overall Study

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Started	70	87	80
Completed	53	69	67
Not Completed	17	18	13
Adverse Event	7	7	7
Withdrawal by Subject	5	6	2

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Incorrect enrollment	2	0	0
Protocol Violation	1	1	1
Lost to Follow-up	1	1	2
Study specific discontinuation criteria	0	0	1
Visit 10 was performed earlier	0	1	0
Pregnancy	1	2	0

Baseline Characteristics

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Baseline Measures

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg	Total
Number of Participants	70	87	80	237
Age, Customized [units: Participants]				
18 to 49 years	34	44	42	120
50 to 64 years	31	31	30	92
>=65 years	5	12	8	25
Gender, Male/Female [units: Participants]				
Female	28	35	31	94
Male	42	52	49	143
Estimated glomerular filtration rate [eGFR] [units: mL/min] Mean (Standard Deviation)	78.315 (28.0653)	76.774 (30.3878)	71.464 (30.0156)	75.419 (29.6012)

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg	Total
Urine albumin/creatinine ratio [units: mg/g] Mean (Standard Deviation)	1023.165 (720.0251)	1167.368 (865.4584)	1069.103 (720.8011)	1091.263 (775.1889)
Urine protein/creatinine ratio [units: mg/g] Mean (Standard Deviation)	1301.163 (832.7398)	1487.131 (1068.0642)	1439.720 (991.2295)	1416.023 (975.7636)

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
Measure Description	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time Frame	Assessed at baseline and Week 52 (LOCF)
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	65	80	75
Urinary Protein/Creatinine Ratio at Week 52 [LOCF] [units: ratio] Geometric Mean (95% Confidence Interval)	0.938 (0.725 to 1.212)	1.082 (0.927 to 1.262)	0.759 (0.636 to 0.905)

2. Secondary Outcome Measure:

Measure Title	Urinary Protein/Creatinine Ratio at Week 26.
Measure Description	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time Frame	Assessed at baseline and Week 26
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	59	76	70
Urinary Protein/Creatinine Ratio at Week 26. [units: ratio] Geometric Mean (95% Confidence Interval)	0.932 (0.721 to 1.203)	1.057 (0.898 to 1.244)	0.762 (0.631 to 0.921)

3. Secondary Outcome Measure:

Measure Title	Urinary Albumin/Creatinine Ratio at Week 26
Measure Description	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time Frame	Assessed at baseline and Week 26
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	60	76	72
Urinary Albumin/Creatinine Ratio at Week 26 [units: ratio] Geometric Mean (95% Confidence Interval)	0.850 (0.631 to 1.143)	0.946 (0.789 to 1.135)	0.731 (0.601 to 0.889)

4. Secondary Outcome Measure:

Measure Title	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Measure Description	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time Frame	Assessed at baseline and Week 52 [LOCF]
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	65	80	75

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] [units: ratio] Geometric Mean (95% Confidence Interval)	0.879 (0.652 to 1.185)	0.967 (0.814 to 1.148)	0.719 (0.587 to 0.882)

5. Secondary Outcome Measure:

Measure Title	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Measure Description	The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
Time Frame	Assessed at baseline and Week 26
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	60	77	72
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 [units: mL/min] Mean (Standard Deviation)	1.39 (15.431)	-3.41 (13.228)	-1.61 (9.494)

6. Secondary Outcome Measure:

Measure Title	Change From Baseline in eGFR at Week 52 [LOCF]
Measure Description	The change from baseline in eGFR at Week 52 [LOCF] is the Week 52 value or last observation carried forward minus baseline value.

Time Frame	Assessed at baseline and Week 52 [LOCF]
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Measured Values

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Number of Participants Analyzed	65	80	75
Change From Baseline in eGFR at Week 52 [LOCF] [units: mL/min] Mean (Standard Deviation)	-2.71 (13.083)	-3.30 (12.325)	-1.74 (13.964)

7. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled

	Description
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	70	205
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. [units: Correlation coefficient]	0.17601	0.21701	0.19643

8. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	64	185

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. [units: Correlation coefficient]	0.20462	0.03480	0.16077

9. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 [units: Correlation coefficient]	0.14302	0.24393	0.17632

10. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C [units: Correlation coefficient]	0.16868	-0.09428	0.10679

11. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 [units: Correlation coefficient]	0.18055	0.24987	0.22094

12. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 [units: Correlation coefficient]	0.20346	0.18041	0.20818

13. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 [units: Correlation coefficient]	0.16206	0.20032	0.17628

14. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 [units: Correlation coefficient]	0.20386	-0.04698	0.14495

15. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	70	205
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 [units: Correlation coefficient]	0.15348	-0.06049	0.10089

16. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	64	185
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 [units: Correlation coefficient]	0.20659	0.23989	0.21728

17. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.04652	0.06344	0.04149

18. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.03957	-0.17644	-0.01549

19. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.06383	0.12687	0.07462

20. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.05881	-0.20262	-0.01340

21. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	135	69	204
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.06794	0.05410	0.05465

22. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	62	183
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.07188	-0.16669	0.00955

23. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	67	198

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 [units: Correlation coefficient]	0.12595	0.05628	0.13754

24. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	62	178
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 [units: Correlation coefficient]	0.19626	0.09835	0.18349

25. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	67	198
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 [units: Correlation coefficient]	0.18504	0.17259	0.19146

26. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	62	178
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 [units: Correlation coefficient]	0.18473	-0.02690	0.12496

27. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	67	198
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 [units: Correlation coefficient]	0.10698	0.13814	0.11414

28. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	62	178

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 [units: Correlation coefficient]	0.05859	-0.12938	-0.00540

29. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	72	208
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 [units: Correlation coefficient]	0.18188	0.17503	0.18566

30. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	65	186
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 [units: Correlation coefficient]	0.23734	0.01311	0.17958

31. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 [units: Correlation coefficient]	0.14783	0.21561	0.16899

32. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 [units: Correlation coefficient]	0.20285	-0.13565	0.12568

33. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 [units: Correlation coefficient]	0.23547	0.25043	0.25208

34. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 [units: Correlation coefficient]	0.17479	0.18677	0.18203

35. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 [units: Correlation coefficient]	0.16080	0.17150	0.16578

36. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 [units: Correlation coefficient]	0.24107	-0.08640	0.16525

37. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	72	208
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 [units: Correlation coefficient]	0.11526	-0.06890	0.07248

38. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	65	186

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 [units: Correlation coefficient]	0.21730	0.21151	0.21477

39. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.02506	0.02201	0.01860

40. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.08954	-0.20870	0.01926

41. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.05037	0.09779	0.05936

42. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.10365	-0.24717	0.01386

43. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	136	71	207

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.04955	0.02740	0.03798

44. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	0.11997	-0.21073	0.03955

45. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	68	199
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 [units: Correlation coefficient]	0.16499	0.02609	0.15049

46. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 [units: Correlation coefficient]	0.20021	0.12953	0.18870

47. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	68	199
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 [units: Correlation coefficient]	0.18720	0.16167	0.18717

48. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179

	Rosuvastatin	Atorvastatin	All Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 [units: Correlation coefficient]	0.21082	-0.04379	0.14085

49. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	131	68	199
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 [units: Correlation coefficient]	0.10258	0.13505	0.11103

50. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Measure Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 [units: Correlation coefficient]	0.08108	-0.16753	0.00479

51. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	72	209
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 [units: Correlation coefficient]	0.06641	-0.07964	0.02900

52. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	65	186
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 [units: Correlation coefficient]	-0.15721	0.16110	-0.05794

53. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 [units: Correlation coefficient]	0.02679	-0.07603	-0.00171

54. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 [units: Correlation coefficient]	-0.15731	0.15368	-0.06310

55. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 [units: Correlation coefficient]	0.01684	0.01755	0.01758

56. Secondary Outcome Measure:

Measure Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 [units: Correlation coefficient]	0.14080	0.02750	0.09472

57. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 [units: Correlation coefficient]	0.06029	-0.08151	0.02283

58. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 [units: Correlation coefficient]	-0.19532	0.14967	-0.09001

59. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	72	209
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 [units: Correlation coefficient]	0.04160	0.00531	0.03430

60. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	65	186
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG [units: Correlation coefficient]	-0.12643	0.00486	-0.08301

61. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.08194	-0.06576	0.04477

62. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 [units: Correlation coefficient]	-0.23597	0.19933	-0.10205

63. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.04858	-0.05535	0.02023

64. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	-0.20805	0.18299	-0.07681

65. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	137	71	208
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 [units: Correlation coefficient]	0.08263	-0.06860	0.04337

66. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	121	63	184
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 [units: Correlation coefficient]	-0.23887	0.17170	-0.10817

67. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	132	68	200
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 [units: Correlation coefficient]	0.13029	0.17554	0.14191

68. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment

	Description
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 [units: Correlation coefficient]	0.11047	0.07751	0.08580

69. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	132	68	200
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 [units: Correlation coefficient]	0.06098	-0.03181	0.03861

70. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 [units: Correlation coefficient]	-0.11217	0.11006	-0.03932

71. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	132	68	200
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 [units: Correlation coefficient]	0.02907	-0.09476	-0.00160

72. Secondary Outcome Measure:

Measure Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Measure Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Rosuvastatin	Rosuvastatin Treatments pooled
Atorvastatin	Atorvastatin Treatment
All Treatments	All Treatments pooled

Measured Values

	Rosuvastatin	Atorvastatin	All Treatments
Number of Participants Analyzed	116	63	179
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 [units: Correlation coefficient]	-0.15415	0.10486	-0.06121

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	[Not specified]

Reporting Groups

	Description
Rosuvastatin 10 mg	
Rosuvastatin 40 mg	
Atorvastatin 80 mg	

Serious Adverse Events

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	10/69 (14.49%)	6/87 (6.9%)	5/80 (6.25%)
Cardiac disorders			
Cardiac Failure [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Cardiac Failure Congestive [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Gastrointestinal disorders			
Dyspepsia [A] †	0/69 (0%)	0/87 (0%)	1/80 (1.25%)

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Enterocolitis [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Gastritis [A] †	0/69 (0%)	0/87 (0%)	1/80 (1.25%)
Gastrointestinal Haemorrhage [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
General disorders			
Oedema Peripheral [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
Infections and infestations			
Bronchitis [A] †	2/69 (2.9%)	0/87 (0%)	1/80 (1.25%)
Injury, poisoning and procedural complications			
Humerus Fracture [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
Lumbar Vertebral Fracture [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Meniscus Lesion [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
Metabolism and nutrition disorders			
Fluid Retention [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Musculoskeletal and connective tissue disorders			
Intervertebral Disc Protrusion [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Musculoskeletal Chest Pain [A] †	0/69 (0%)	0/87 (0%)	1/80 (1.25%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast Cancer [A] †	0/69 (0%)	0/87 (0%)	1/80 (1.25%)
Transitional Cell Carcinoma [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Nervous system disorders			
Hypertensive Encephalopathy [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Intracranial Aneurysm [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
Renal and urinary disorders			

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Nephrotic Syndrome [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)
Renal Colic [A] †	1/69 (1.45%)	0/87 (0%)	0/80 (0%)
Respiratory, thoracic and mediastinal disorders			
Epistaxis [A] †	0/69 (0%)	0/87 (0%)	1/80 (1.25%)
Vascular disorders			
Hypertension [A] †	0/69 (0%)	1/87 (1.15%)	0/80 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 12.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	15/69 (21.74%)	16/87 (18.39%)	17/80 (21.25%)
Gastrointestinal disorders			
Nausea [A] †	2/69 (2.9%)	6/87 (6.9%)	0/80 (0%)
Infections and infestations			
Blood Creatine Phosphokinase Increased [A] †	3/69 (4.35%)	3/87 (3.45%)	4/80 (5%)
Bronchitis [A] †	4/69 (5.8%)	0/87 (0%)	0/80 (0%)
Nasopharyngitis [A] †	3/69 (4.35%)	6/87 (6.9%)	7/80 (8.75%)
Musculoskeletal and connective tissue disorders			
Myalgia [A] †	4/69 (5.8%)	3/87 (3.45%)	5/80 (6.25%)
Nervous system disorders			
Dizziness [A] †	0/69 (0%)	1/87 (1.15%)	4/80 (5%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 12.0

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.

Results Point of Contact:

Name/Official Title: Gerard Lynch
Organization: AstraZeneca
Phone:
Email: aztrial_results_posting@astrazeneca.com